# World Journal of *Clinical Cases*

World J Clin Cases 2023 October 6; 11(28): 6670-6973





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

#### Contents

Thrice Monthly Volume 11 Number 28 October 6, 2023

#### **MINIREVIEWS**

6670 Neurotransmitters regulate  $\beta$  cells insulin secretion: A neglected factor

Kong CC, Cheng JD, Wang W

#### **ORIGINAL ARTICLE**

#### **Case Control Study**

Factors influencing the surveillance of re-emerging intracranial infections in elective neurosurgical 6680 patients: A single-center retrospective study

Wang JL, Wu XW, Wang SN, Liu X, Xiao B, Wang Y, Yu J

#### **Retrospective Study**

6688 Clinical value of chemiluminescence method for detection of antinuclear antibody profiles

Xiang HY, Xiang XY, Ten TB, Ding X, Liu YW, Luo CH

6698 Value of ultrasound guided biopsy combined with Xpert Mycobacterium tuberculosis/resistance to rifampin assay in the diagnosis of chest wall tuberculosis

Yan QH, Chi JY, Zhang L, Xue F, Cui J, Kong HL

6707 Research on the intelligent internet nursing model based on the child respiratory and asthma control test scale for asthma management of preschool children

Pei CF, Zhang L, Xu XY, Qin Z, Liang HM

6715 Effects of different doses of long-acting growth hormone in treating children with growth hormone deficiency

Xia W, Wang T, Pan JY

6725 Efficacy and anti-inflammatory analysis of glucocorticoid, antihistamine and leukotriene receptor antagonist in the treatment of allergic rhinitis

Qiu C, Feng D

6733 Subchondral fatigue fracture of the femoral head in young military recruits: Potential risk factors

Yang JZ, Chen P, Chen BH, Zhao B

6744 Anemia status of infants and young children aged six to thirty-six months in Ma'anshan City: A retrospective study

Wang XM, Wang QY, Huang J

#### **Observational Study**

6754 Impact of coronary artery bypass grafting surgery on the chorioretinal biomicroscopic characteristics Shahriari M, Nikkhah H, Mahjoob MP, Behnaz N, Barkhordari S, Cheraqpour K



#### Contents

Thrice Monthly Volume 11 Number 28 October 6, 2023

#### **Prospective Study**

6763 Effects of humanized nursing care on negative emotions and complications in patients undergoing hysteromyoma surgery

Liu L, Xiao YH, Zhou XH

#### **Randomized Controlled Trial**

6774 Randomized controlled trial on the efficacy and safety of autologous serum eye drops in dry eye syndrome Zheng N, Zhu SQ

#### SYSTEMATIC REVIEWS

6782 Primary adrenal Ewing sarcoma: A systematic review of the literature Manatakis DK, Tsouknidas I, Mylonakis E, Tasis NP, Antonopoulou MI, Acheimastos V, Mastoropoulou A, Korkolis DP

#### **CASE REPORT**

- 6792 Pulmonary artery aneurysm protruding into the bronchus as an endobronchial mass: A case report Li M, Zhu WY, Wu RR, Wang L, Mo MT, Liu SN, Zhu DY, Luo Z
- 6797 Rare rectal gastrointestinal stromal tumor case: A case report and review of the literature Dong RX, Wang C, Zhou H, Yin HQ, Liu Y, Liang HT, Pan YB, Wang JW, Cao YQ
- 6806 Bilateral retinal nerve fiber layer thickness reduction in a 9-year-old myopic boy suffering from unilateral optic neuritis: A case report

Zhao FF, Yao SQ, Wang Y, Li TP, Yang JF, Pang CP, Cen LP

6812 Application of negative pressure wound therapy after skin grafting in the treatment of skin cancer: A case report

Huang GS, Xu KC

- 6817 Diagnosis and treatment of McCune-Albright syndrome: A case report Lin X, Feng NY, Lei YJ
- 6823 Paraneoplastic myopathy-related rhabdomyolysis and pancreatic cancer: A case report and review of the literature Costantini A, Moletta L, Pierobon ES, Serafini S, Valmasoni M, Sperti C

6831 Multi-organ hereditary hemorrhagic telangiectasia: A case report Chen YL, Jiang HY, Li DP, Lin J, Chen Y, Xu LL, Gao H

6841 Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report

Yang HY, Du YX, Hou YJ, Lu DR, Xue P

6850 Effectiveness of antidepressant repetitive transcranial magnetic stimulation in a patient with refractory psychogenic dysphagia: A case report and review of literature

Woo CG, Kim JH, Lee JH, Kim HJ



Conton	World Journal of Clinical Cases
Conten	Thrice Monthly Volume 11 Number 28 October 6, 2023
6857	Entrapment neuropathy of common peroneal nerve by fabella: A case report
	Lin JC, Tsai MH, Lin WP, Kuan TS, Lien WC
6864	Importance of accurate diagnosis of congenital agenesis of the gallbladder from atypical gallbladder stone presentations: A case report
	Sun HJ, Ge F, Si Y, Wang Z, Sun HB
6871	Dorsal approach for isolated volar fracture-dislocation of the base of the second metacarpal: A case report
	Kurozumi T, Saito M, Odachi K, Masui F
6877	Rotationplasty type BIIIb as an effective alternative to limb salvage procedure in adults: Two case reports
	Chen ZX, Guo XW, Hong HS, Zhang C, Xie W, Sha M, Ding ZQ
6889	Primary cutaneous anaplastic large cell lymphoma with over-expressed Ki-67 transitioning into systemic anaplastic large cell lymphoma: A case report
	Mu HX, Tang XQ
6895	Confusing finding of quantitative fluorescent polymerase chain reaction analysis in invasive prenatal genetic diagnosis: A case report
	Chen C, Tang T, Song QL, He YJ, Cai Y
6902	Testicular mixed germ cell tumor: A case report
	Xiao QF, Li J, Tang B, Zhu YQ
6908	Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature
	Xiu NN, Yang XD, Xu J, Ju B, Sun XY, Zhao XC
6920	Pancreatic arteriovenous malformation treated with transcatheter arterial embolization: Two case reports and review of literature
	Shin SH, Cho CK, Yu SY
6931	Cecal duplication cyst in an infant presenting as shock: A case report
	Kim SM, Lee SH, Park GY, Kim SS, Lee CG, Jin SJ
6938	Pulmonary reversed halo cycles and consolidations after immunotherapy: A case report
	Suo H, Shi YJ, Huang ZD, Xu K, Huang H
6943	Unusual case of emphysematous cystitis mimicking intestinal perforation: A case report
	Kang HY, Lee DS, Lee D
6949	Malignant proliferative ependymoma of the neck with lymph node metastasis: A case report
	Wang K, Wen JZ, Zhou SX, Ye LF, Fang C, Chen Y, Wang HX, Luo X
6955	Wandering spleen torsion with portal vein thrombosis: A case report
	Zhu XY, Ji DX, Shi WZ, Fu YW, Zhang DK



Conto	World Journal of Clinical Cases
Conte	Thrice Monthly Volume 11 Number 28 October 6, 2023
6961	Intracranial infection and sepsis in infants caused by <i>Salmonella derby</i> : A case report <i>Yu JL, Jiang LL, Dong R, Liu SY</i>
6967	Large gastric hamartomatous inverted polyp accompanied by advanced gastric cancer: A case report <i>Park G, Kim J, Lee SH, Kim Y</i>

#### Contents

Thrice Monthly Volume 11 Number 28 October 6, 2023

#### **ABOUT COVER**

Editorial Board Member of World Journal of Clinical Cases, Hao Wang, MD, PhD, Associate Professor, Department of Emergency Medicine, John Peter Smith Health Network, Texas Christian University and University of North Texas Health Science Center, School of Medicine, Fort Worth, TX 76104, United States. hwang@ies.healthcare

#### **AIMS AND SCOPE**

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

#### **INDEXING/ABSTRACTING**

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

#### **RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Si Zhao; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS	
World Journal of Clinical Cases	https://www.wjgnet.com/bpg/gerinfo/204	
<b>ISSN</b>	GUIDELINES FOR ETHICS DOCUMENTS	
ISSN 2307-8960 (online)	https://www.wjgnet.com/bpg/GerInfo/287	
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH	
April 16, 2013	https://www.wjgnet.com/bpg/gerinfo/240	
FREQUENCY	PUBLICATION ETHICS	
Thrice Monthly	https://www.wjgnet.com/bpg/GerInfo/288	
<b>EDITORS-IN-CHIEF</b> Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku	PUBLICATION MISCONDUCT https://www.wjgnet.com/bpg/gerinfo/208	
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE	
https://www.wjgnet.com/2307-8960/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242	
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS	
October 6, 2023	https://www.wjgnet.com/bpg/GerInfo/239	
COPYRIGHT	ONLINE SUBMISSION	
© 2023 Baishideng Publishing Group Inc	https://www.f6publishing.com	

© 2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



W J C C World Journal C Clinical Cases

# World Journal of

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2023 October 6; 11(28): 6774-6781

DOI: 10.12998/wjcc.v11.i28.6774

ISSN 2307-8960 (online)

ORIGINAL ARTICLE

#### **Randomized Controlled Trial**

## Randomized controlled trial on the efficacy and safety of autologous serum eye drops in dry eye syndrome

#### Na Zheng, Si-Quan Zhu

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

#### Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B Grade C (Good): C Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Howitt BE, United States; Smith SC, United States

Received: August 8, 2023 Peer-review started: August 8, 2023 First decision: August 24, 2023 Revised: August 31, 2023 Accepted: September 14, 2023 Article in press: September 14, 2023 Published online: October 6, 2023



Na Zheng, Department of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu 610032, Sichuan Province, China

Si-Quan Zhu, Department of Ophthalmology, Beijing Anzhen Hospital Affiliated to China Medical University, Beijing 100029, China

Corresponding author: Si-Quan Zhu, MD, Chief Doctor, Department of Ophthalmology, Beijing Anzhen Hospital Affiliated to China Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China. gveuhxsb@yeah.net

#### Abstract

#### BACKGROUND

Autologous serum eye drops (ASEDs), a novel treatment derived from blood serum, have emerged as a groundbreaking solution for managing dry eye syndrome (DES). These drops have shown significant promise in relieving the distressing symptoms of DES. This study aimed to evaluate the safety and effectiveness of ASEDs compared to traditional treatments, which often prove inadequate or resu-It in unwanted side effects, particularly in individuals with moderate-to-severe DES.

#### AIM

To evaluate whether ASEDs are safer and more effective than conventional artificial tears in the treatment of moderate-to-severe DES.

#### **METHODS**

This multi-centered randomized controlled trial included 240 patients with moderate-to-severe DES from three ophthalmology clinics in China. They were randomly assigned to receive either ASEDs or artificial tears for 12 wk. The primary outcome was the change in the ocular surface disease index (OSDI) score, with secondary outcomes including tear break-up time (TBUT), Schirmer I test, corneal fluorescein staining (CFS), and conjunctival impression cytology (CIC). Statistics analysis was performed using an analysis of covariance with adjustments made for baseline values.

#### RESULTS

Our findings revealed that both ASEDs and artificial tears significantly improved the OSDI score, TBUT, Schirmer I test, CFS, and CIC from baseline to week 12. The ASEDs group showed significantly greater improvement in all these mea-



sures than the artificial tears group (all *P* values < 0.05). The average difference in the OSDI score between the two cohorts was -10.3 (95% confidence interval: -13.6 to -7.0), indicating a substantial improvement in the ASEDs group. The occurrence of adverse events was comparable between cohorts, with no reports of severe adverse events.

#### CONCLUSION

ASEDs are more effective and safer than artificial tears for mitigating symptoms of moderate-to-severe DES. ASEDs could be an alternative/supplementary therapy for patients with DES less responsive to traditional treatments.

**Key Words:** Autologous serum eye drops; Dry eye syndrome; Safety; Effectiveness; Alternative therapy; Conventional artificial tears

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Autologous serum eye drops (ASEDs) are safe and effective alternative therapies for managing moderate-to-severe dry eye syndrome (DES). The study comparing ASEDs to conventional artificial tears found that ASEDs significantly improved the ocular surface disease index score, tear break-up time, Schirmer I test, corneal fluorescein staining, and conjunctival impression cytology over 12 wk. The ASEDs group showed greater improvement in these measures than the artificial tears group. Moreover, no severe adverse events were reported, indicating the safety of the ASEDs. These findings suggest that ASEDs are a valuable treatment option for patients with DES who respond poorly to traditional therapies.

Citation: Zheng N, Zhu SQ. Randomized controlled trial on the efficacy and safety of autologous serum eye drops in dry eye syndrome. *World J Clin Cases* 2023; 11(28): 6774-6781 URL: https://www.wjgnet.com/2307-8960/full/v11/i28/6774.htm DOI: https://dx.doi.org/10.12998/wjcc.v11.i28.6774

#### INTRODUCTION

Dry eye syndrome (DES) is a multifaceted condition that affects the surface of the eye, leading to a variety of uncomfortable symptoms such as burning, itching, foreign body sensation, dryness, and blurred vision. Additionally, DES is characterized by signs such as tear film instability, hyperosmolarity, inflammation, and damage to the corneal and conjunctival epithelium[1]. It is a significant global health concern, with an estimated prevalence of 5%-35% worldwide. Factors such as age, sex (with females are more affected), environmental conditions, systemic diseases, and medication use can contribute to its prevalence[2]. Beyond physical discomfort, DES can significantly affect an individual's daily life, disrupt routine tasks, reduce work productivity, affect social interactions, and even affect mental health[3]. Moreover, DES increases the risk of ocular infections and complications owing to weakened tear defense mechanisms and damage to the epithelial integrity of the eye[4]. Thus, DES not only causes physical discomfort but also poses serious health risks.

The pathophysiology of DES is complex and involves multiple factors that interact in a vicious cycle<sup>[5]</sup>. Reduced tear production by the lacrimal glands, increased tear evaporation due to meibomian gland dysfunction, or eyelid abnormalities are the main factors that lead to tear film hyperosmolarity, triggering inflammatory cascades that release inflammatory mediators, matrix-degrading enzymes, and reactive oxygen-based compounds<sup>[6,7]</sup>. These mediators further damage the ocular surface epithelium, thereby reducing its barrier function, allowing more evaporation, and exposing the eyes to environmental irritants<sup>[8]</sup>. The damaged epithelium also releases inflammatory mediators that stimulate sensory nerves, causing neurogenic inflammation and pain, which further affects the lacrimal gland function and reduces its secretory capacity<sup>[9,10]</sup>.

Consequently, DES treatment aims to restore tear film stability and quality, reduce inflammation and pain, and prevent complications[11]. Conventional treatments include artificial tears, anti-inflammatory agents (cyclosporine A or corticosteroids), punctal occlusion, dietary supplements, and oral medications (doxycycline and pilocarpine)[12]. However, these therapies are often insufficient to control the signs and symptoms of DES, particularly in moderate-to-severe cases. Moreover, some of these therapies have potential adverse effects, including ocular irritation, infection, glaucoma, and systemic toxicity[13].

Autologous serum eye drops (ASEDs) are a novel treatment modality that utilize the patient's blood serum as a source of tear substitutes. ASEDs contain various growth factors, cytokines, vitamins, antioxidants, and other bioactive molecules that occur naturally in tears and promote ocular surface healing and regeneration[14]. Additionally, ASEDs possess anti-inflammatory, anti-apoptotic, anti-microbial, and anti-fibrotic properties, which effectively modulate the immune response and preventing scarring[15]. While ASEDs have shown promise in alleviating the signs and symptoms of various forms of DES, including aqueous-deficient DES, Sjögren's disorder, transplant *vs* host disease, Stevens-Johnson syndrome, and eye-related cicatricial pemphigoid, existing evidence is limited and inconsistent, and high-quality randomized controlled trials (RCTs) have rigorously evaluated ASEDs against artificial tears or traditional therapies[16,17].

Reisbideng® WJCC | https://www.wjgnet.com

To address this knowledge gap, we conducted a randomized, double-blind, parallel-group, controlled experiment to directly compare the efficacy and safety of ASEDs with artificial tears in patients with moderate-to-severe DES. We hypothesized that ASEDs would surpass artificial tears in improving the ocular surface disease index (OSDI) score, a well-established measure of patient-reported outcomes for DES.

#### MATERIALS AND METHODS

#### Study design and participants

This extensive, randomized, double-blind, parallel-group, controlled study was conducted at three ophthalmology clinics in China from January 2022 to June 2023. The research protocol was approved by the ethics committee and conducted in accordance with the principles of the Declaration of Helsinki and Consolidated Standards of Reporting Trials (CON-SORT) guidelines for documenting RCTs. All participants provided written informed consent before participation.

To be eligible for the study, participants were required to be at least 18 years old and diagnosed with moderate-tosevere DES according to the 2017 International Dry Eye Workshop criteria. Additionally, they were required to have an OSDI score of 23 or higher, a tear break-up time (TBUT) of 5 s or less, a Schirmer I test result of 5 mm/5 min or less, a corneal fluorescein staining (CFS) score of 2 or higher, and a commitment to comply with the study procedures and follow-up appointments.

Participants were excluded from the study if they had a history of allergy or adverse reactions to blood products or artificial tears, had undergone eye surgery, experienced trauma within the past six months, or had an ocular infection or inflammation within the past three months. Other exclusion criteria included the use of topical or systemic medications that could affect tear production or the ocular surface in the past four weeks (such as corticosteroids, cyclosporine A, antihistamines, antidepressants, or diuretics), use of contact lenses within the past four weeks, pregnancy or lactation, presence of any other ocular or systemic disease that could interfere with the study outcomes, participation in another clinical trial within the past three months, and inability to provide blood samples for ASEDs preparation.

#### Randomization and masking

Qualified participants were randomly assigned to receive either ASEDs or artificial tears. Randomization was achieved using a computer-generated sequence with a block size of four to ensure a balanced 1:1 ratio. The allocation was concealed using sealed opaque envelopes that were opened by an independent pharmacist only after the participants were enrolled. To maintain study integrity, all parties involved-participants, investigators, outcome assessors, and data analysts-remained blinded to group assignments throughout the study. Both ASEDs and artificial tears were packaged in identical bottles, each labeled with a unique code by the pharmacist. This code was securely stored in a locked cabinet and was not accessed until the end of the study, further ensuring blinding.

#### Interventions

Participants in the ASEDs group received eye drops prepared from their blood serum following a standardized protocol. Specifically, 40 mL of venous blood was collected from each participant at the start of the study and centrifuged at 3000 rpm for 15 min. The supernatant serum was transferred to sterile vials and diluted with saline solution to achieve a final serum concentration of 20 %. These vials were stored at -80 °C until needed. Each participant received four vials (10 mL each) per month and was instructed to thaw one vial at a time at room temperature and store it in a refrigerator for up to one week. Further, they were instructed to apply one drop of ASEDs to each eye, four times daily, for 12 wk. Participants in the artificial tears group received commercially available preservative-free eye drops containing 0.1% sodium hyaluronate (Hylo-Comod®, Germany). They were instructed to apply one drop of artificial tears to each eye four times daily for 12 wk. Participants were advised against using any other eye drops or medications during the study period. They were also instructed to maintain their usual lifestyle and environmental conditions and to report any adverse events or changes in their health status to the investigators.

#### Outcomes

The primary objective of this study was to monitor changes in the OSDI scores over 12 wk. The OSDI is a comprehensive 12-item questionnaire used to assess the frequency and severity of eye symptoms, the influence of environmental triggers, and the impact of DES on vision-related functionality. The OSDI scores range from 0 to 100, with higher scores indicating greater ocular discomfort and impairment.

In addition to primary outcomes, this study evaluated several secondary outcomes. These included changes in the TBUT, Schirmer I test, CFS, and conjunctival impression cytology (CIC) over the 12-wk study period. The TBUT is a valuable metric for evaluating tear film stability. This test involved the application of a droplet of fluorescein dye to the lower conjunctival sac, followed by the measurement of the time elapsed from a complete blink until the first dry spot appeared on the cornea. The results were expressed in seconds, with lower values indicating rapid tear evaporation and instability[18].

The Schirmer I test was used to quantify the tear production. This test involved placing a standardized filter paper strip at the intersection of the middle and outer third of the lower eyelid edge. After a five-minute waiting period without anesthesia, the length of wetting was measured. The results were expressed in millimeters, with lower values indicating reduced tear secretion[19].

WJCC | https://www.wjgnet.com

The CFS serves as a metric to gauge the extent of corneal epithelial damage. To conduct this assessment, a drop of fluorescein dye was carefully placed in the lower conjunctival sac, followed by an evaluation of the corneal staining pattern using the Oxford grading system. The resulting CFS score, ranging from 0 to 15, provides valuable insights into the severity of induced staining and associated harm[20].

Furthermore, conjunctival epithelial morphology and inflammation were effectively evaluated using CIC. This assessment involved the gentle application of a cellulose acetate filter paper to the temporal bulbar conjunctiva for a brief duration of 5 s. Subsequently, the stained filter paper was carefully examined under a light microscope using periodic acid-Schiff and hematoxylin-eosin staining. Noteworthy observations included the presence of goblet cells, squamous metaplasia, and inflammatory cells. The resulting CIC score, which ranges from 0 to 3, provides valuable information to practitioners about the presence of any abnormal cytology and inflammation<sup>[21]</sup>.

Moreover, it was of utmost importance to systematically record any adverse events encountered during the study. These events were classified as mild, moderate, or severe, based on their intensity and apparent connection to the study interventions. This comprehensive evaluation allowed for a thorough investigation of any potential adverse outcomes of the interventions, ensuring a comprehensive analysis of the overall study effects.

#### Sample size

To ensure the rigor and robustness of our study, we carefully determined the sample size based on the primary outcome measure, the OSDI score. Our goal was to detect clinically significant improvements, specifically a mean difference of 10 points, between the two groups. To perform this calculation, we considered a standard deviation of 15 points, an alpha value of 0.05, and a statistical power of 0.8. Considering these essential factors, our initial estimation suggested that 96 participants in each group would be sufficient to detect significant differences. However, to account for potential dropouts, we allowed a 10% dropout rate. Consequently, the sample size was increased to 108 participants per group, resulting in a total sample size of 216. This adjustment ensured the comprehensiveness and reliability of the study.

#### Statistical analysis

Statistical analyses were performed using SPSS version 26.0 (IBM Corp., Armonk, NY, United States). Histograms and Kolmogorov-Smirnov tests were used to validate the normal distribution of the data. The baseline characteristics of the two cohorts were compared using independent *t*-tests or Mann-Whitney U tests for continuous variables and  $\chi^2$  tests or Fisher's exact tests for categorical variables. To examine changes in the OSDI score and other secondary outcomes over the 12 wk, an analysis of covariance was employed, with adjustments made for baseline values. Mean differences and 95% confidence intervals (CIs) were calculated. The occurrence of adverse events in the two cohorts was evaluated using the  $\chi^2$  test or Fisher's exact test. A *P* value < 0.05 was considered statistically significant.

#### RESULTS

#### Participant flow and characteristics

A total of 240 participants who voluntarily enrolled in the study were randomly assigned into two groups: ASEDs and artificial tears, with each group comprising 120 individuals. However, four participants from each group withdrew for personal reasons or loss of contact. The final analysis included 232 participants, with 116 participants in both the ASEDs and artificial tears groups.

Analysis of the baseline characteristics of the participants revealed no significant differences between the two cohorts in terms of age, sex, DES duration, DES type, OSDI score, TBUT, Schirmer I test, CFS, or CIC (Table 1). The P values for all comparisons exceeded 0.05, indicating the absence of statistically significant differences between the cohorts.

#### Primary outcome

Table 2 presents the changes in the OSDI scores from the beginning of the study to the 12<sup>th</sup> wk. Both cohorts showed a significant enhancement in OSDI score over time (both P < 0.001). However, the improvement was more significant in the ASEDs group than in the artificial tears group (P < 0.001). The average difference in the OSDI score between the two groups was -10.3 (95% CI: -13.6 to -7.0), indicating a clinically significant improvement in the ASEDs group.

#### Secondary outcomes

Table 2 also presents the variations in the TBUT, Schirmer I test, CFS, and CIC from the start of the investigation to the 12th wk. Both cohorts exhibited significant enhancements in TBUT, Schirmer I test, CFS, and CIC throughout the study (all P < 0.001 between groups). However, the ASEDs group demonstrated significantly greater improvements than the artificial tears group across all measured outcomes (all P < 0.05). The mean differences between the two groups were 1.8 s (95%CI: 1.2-2.4) for TBUT, 3.1 mm (95%CI: 2.3-3.9) for Schirmer I test, -1.5 (95%CI: -1.9 to -1.1) for CFS, and -0.7 (95%CI: -0.9 to -0.5) for CIC.

#### Adverse events

During the data analysis, we observed no significant difference in the occurrence of adverse events between the two cohorts (P = 0.76). No severe adverse events were observed throughout the study. The most frequently observed adverse events included ocular irritation, redness, itching, and discharge. These reactions were generally mild and of short duration.



Table 1 Baseline characteristics of the participants							
Variable	ASEDs group ( <i>n</i> = 116)	Artificial tears group ( <i>n</i> = 116)	<i>P</i> value				
Age (yr)	54.6 ± 12.4	55.2 ± 11.8	0.63				
Sex (female/male)	72/44	69/47	0.72				
Duration of DES (mo)	$18.4 \pm 9.6$	$19.2\pm10.2$	0.51				
Type of DES (aqueous-deficient/evaporative/mixed)	36/28/52	34/30/52	0.91				
OSDI score	$41.8\pm10.4$	$42.1\pm10.6$	0.79				
TBUT (s)	$3.2 \pm 1.1$	$3.3 \pm 1.2$	0.46				
Schirmer I test (mm/5min)	$3.4 \pm 1.6$	$3.5 \pm 1.7$	0.68				
CFS score	$6.7 \pm 2.1$	6.8 ± 2.2	0.75				
CIC score	$2.1 \pm 0.6$	$2.2 \pm 0.7$	0.54				

Data are presented as mean ± SD or number. ASEDs: Autologous serum eye drops; DES: Dry eye syndrome; OSDI: Ocular surface disease index; TBUT: Tear break-up time; CFS: Corneal fluorescein staining; CIC: Conjunctival impression cytology.

Table 2 Changes in ocular surface disease index score and other secondary outcomes from baseline to week 12							
Variable	ASEDs group ( <i>n</i> = 116)	Artificial tears group ( <i>n</i> = 116)	<i>P</i> value				
OSDI score	-26.4 ± 9.8 (-38%)	-16.1 ± 8.9 (-19%)	< 0.001				
TBUT (s)	+2.4 ± 1.3 (+75%)	+0.6 ± 0.9 (+18%)	< 0.001				
Schirmer I test (mm/5 min)	+4.6 ± 2.4 (+135%)	+1.5 ± 1.8 (+43%)	< 0.001				
CFS score	-3.4 ± 1.8 (-51%)	-1.9 ± 1.6 (-28%)	< 0.001				
CIC score	-1.2 ± 0.5 (-57%)	-0.5 ± 0.4 (-23%)	< 0.001				

Data are presented as mean ± SD and percentage change in parentheses. ASEDs: Autologous serum eye drops; OSDI: Ocular surface disease index; TBUT: Tear break-up time; CFS: Corneal fluorescein staining; CIC: Conjunctival impression cytology.

#### DISCUSSION

The results of our research strongly support the effectiveness and safety of ASEDs in treating moderate-to-severe DES compared with artificial tears. A noteworthy finding was the remarkable ten-point reduction in the OSDI score achieved with ASEDs, indicating a significant improvement in ocular comfort and vision-related functionality. Additionally, ASEDs demonstrated positive effects on TBUT, Schirmer I test results, CFS, and CIC, suggesting improved tear film stability and quality, reduced ocular surface inflammation, and enhanced tear production. These results underscore the significant improvements offered by ASEDs. Moreover, the occurrence of adverse events was comparable and mostly mild in both treatment cohorts, indicating an excellent safety profile of ASEDs.

Our results align with those of previous studies highlighting the superiority of ASEDs in treating various forms of DES compared to artificial tears or other standard treatments. For instance, a comprehensive meta-analysis of nine RCTs involving 397 patients with DES demonstrated significant improvements in the OSDI score, TBUT, Schirmer I test, and CFS compared with that by artificial tears or saline solution[22]. Another meta-analysis encompassing seven RCTs with 282 patients with Sjögren's syndrome-related DES found that ASEDs significantly improved the OSDI score, TBUT, Schirmer I test, CFS, and goblet cell density compared with that by artificial tears or cyclosporine A[23]. Furthermore, a systematic review of 16 studies involving 462 patients with severe DES due to ocular surface diseases highlighted the significant benefits of ASEDs in alleviating symptoms, clinical signs, and overall quality of life compared with conventional therapies[24].

However, the precise mechanisms underlying the efficacy of ASEDs remain unclear. However, their composition, which is remarkably similar to that of natural tears, is likely to play a crucial role. ASEDs comprise a potent blend of diverse growth factors, including epidermal growth factor, transforming growth factor-beta, nerve growth factor, vascular endothelial growth factor, and platelet-derived growth factor. Additionally, they contain an array of cytokines, such as interleukin-1 receptor antagonist, tumor necrosis factor-alpha, interferon-gamma, and interleukin-6. Furthermore, ASEDs incorporate essential vitamins, such as vitamins A and E; powerful antioxidants, such as glutathione; and a myriad of other bioactive molecules, including fibronectin, albumin, immunoglobulins, and lysozyme, which are all naturally present in tears[25,26]. These molecules can modulate ocular surface inflammation and immune responses, inhibit pro-inflammatory mediators, reduce oxidative stress, promote epithelial cell proliferation and differentiation,

Raishideng® WJCC | https://www.wjgnet.com

stimulate nerve regeneration, mucin and tear secretion, promote angiogenesis and wound healing, and prevent scarring and fibrosis[27,28]. Additionally, ASEDs possess anti-microbial and anti-fungal properties that may aid in the prevention or treatment of ocular infections[29]. The lubricating effects of the ASEDs may also reduce friction and ocular surface irritation[30].

This study had several strengths. First, it employed a randomized, double-blind, parallel-group controlled design that controlled for confounding variables and minimized bias. Second, the study benefited from a large and rational sample size, allowing for the generalizability of the findings. Third, the preparation and administration of the ASEDs followed a standardized protocol. Fourth, the use of validated and objective outcome measures adds credibility to the study results. Finally, the long follow-up duration allowed for a comprehensive assessment of treatment effects over time. However, this study had some limitations. The study was conducted in a single-country setting, with a lack of a placebo group, potential variability in ASEDs composition among participants, and lack of assessment of the participants' quality of life or cost-effectiveness.

#### CONCLUSION

This study provides robust evidence to support the superiority of ASEDs over artificial tears in terms of improvement. Therefore, ASEDs could be considered a valuable alternative or adjunctive therapy for patients with DES who are refractory to conventional treatment.

#### ARTICLE HIGHLIGHTS

#### Research background

Autologous serum eye drops (ASEDs) have emerged as a groundbreaking solution for managing dry eye syndrome (DES).

#### Research motivation

This study aimed to evaluate the safety and effectiveness of ASEDs compared to traditional treatments for moderate-tosevere DES.

#### **Research objectives**

The main objective of this study was to evaluate the safety and effectiveness of ASEDs compared to conventional artificial tears in the treatment of moderate-to-severe DES.

#### Research methods

A multi-centered randomized controlled trial (RCT) was conducted involving 240 patients from three ophthalmology clinics in China. The primary outcome was the change in the ocular surface disease index (OSDI) score, with secondary outcomes including tear break-up time (TBUT), Schirmer I test, corneal fluorescein staining (CFS), and conjunctival impre -ssion cytology (CIC).

#### Research results

Results showed that ASEDs were significantly more effective than artificial tears in improving these measures without severe adverse events. ASEDs are considered a valuable alternative therapy for DES patients unresponsive to traditional treatments.

#### Research conclusions

The study demonstrated that ASEDs are both more effective and safer than conventional artificial tears for the treatment of moderate-to-severe DES. The ASEDs group exhibited significant improvements in the OSDI score, TBUT, Schirmer I test, CFS, and CIC compared to the artificial tears group. The average difference in the OSDI score between the two groups was substantial, indicating a notable improvement in the ASEDs group. Importantly, no severe adverse events were reported in either group. These findings establish ASEDs as a valuable alternative or supplementary therapy for DES patients who do not respond well to traditional treatments.

#### Research perspectives

The research findings highlight the potential of ASEDs as a promising therapy for moderate-to-severe DES. Further studies could explore the long-term effects of ASEDs and compare their efficacy with other emerging treatments. Additionally, investigating the underlying mechanisms of action of ASEDs and identifying patient characteristics that predict treatment response would contribute to personalized treatment approaches. Cost-effectiveness analyses and evaluations in diverse populations would provide valuable insights into the broader applicability of ASEDs. Furthermore, exploring combination therapies incorporating ASEDs and evaluating their synergistic effects may yield enhanced outcomes for DES management. Continued research and clinical trials are warranted to advance the understanding and implementation of ASEDs in the field of ophthalmology.



#### FOOTNOTES

Author contributions: Zheng N proposed the concept of this study, guided research, and drafted the first draft; Zhu SQ and Zheng N contributed to the data collection, survey, visualization of this study, and also validated this study, reviewed and edited the manuscript; Zhu SQ contributed to formal analysis and the methods.

Institutional review board statement: This study was reviewed and approved by the Medical Ethics Committee of the School of Ophthalmology, Chengdu University of Traditional Chinese Medicine.

Clinical trial registration statement: This study was registered at the Clinical Medical Center The registration identification number is Researchregistry8973.

Informed consent statement: This study has obtained informed consent from the patient or guardian.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

Data sharing statement: No additional data are available.

CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

#### Country/Territory of origin: China

ORCID number: Na Zheng 0009-0004-9261-0929; Si-Quan Zhu 0009-0006-6521-8846.

S-Editor: Wang IJ L-Editor: A P-Editor: Wang JJ

#### REFERENCES

- Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017; 15: 276-283 [PMID: 28736335 DOI: 10.1016/j.jtos.2017.05.008]
- 2 Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, Viso E, Vitale S, Jones L. TFOS DEWS II Epidemiology Report. Ocul Surf 2017; 15: 334-365 [PMID: 28736337 DOI: 10.1016/j.jtos.2017.05.003]
- Mizuno Y, Yamada M, Miyake Y; Dry Eye Survey Group of the National Hospital Organization of Japan. Association between clinical 3 diagnostic tests and health-related quality of life surveys in patients with dry eye syndrome. Jpn J Ophthalmol 2010; 54: 259-265 [PMID: 20700790 DOI: 10.1007/s10384-010-0812-2]
- Shtein RM. Post-LASIK dry eye. Expert Rev Ophthalmol 2011; 6: 575-582 [PMID: 22174730 DOI: 10.1586/eop.11.56] 4
- Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, 5 Sullivan DA. TFOS DEWS II pathophysiology report. Ocul Surf 2017; 15: 438-510 [PMID: 28736340 DOI: 10.1016/j.jtos.2017.05.011]
- Green-Church KB, Butovich I, Willcox M, Borchman D, Paulsen F, Barabino S, Glasgow BJ. The international workshop on meibomian 6 gland dysfunction: report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease. Invest Ophthalmol Vis Sci 2011; 52: 1979-1993 [PMID: 21450916 DOI: 10.1167/iovs.10-6997d]
- Chao C, Tong L. Tear Lactoferrin and Features of Ocular Allergy in Different Severities of Meibomian Gland Dysfunction. Optom Vis Sci 7 2018; 95: 930-936 [PMID: 30234832 DOI: 10.1097/OPX.000000000001285]
- Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012; 130: 90-100 [PMID: 22232476 DOI: 10.1001/archophthalmol.2011.364]
- 9 Hamrah P, Liu Y, Zhang Q, Dana MR. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch Ophthalmol 2003; 121: 1132-1140 [PMID: 12912691 DOI: 10.1001/archopht.121.8.1132]
- Zhang X, Chen W, De Paiva CS, Corrales RM, Volpe EA, McClellan AJ, Farley WJ, Li DQ, Pflugfelder SC. Interferon-y exacerbates dry eye-10 induced apoptosis in conjunctiva through dual apoptotic pathways. Invest Ophthalmol Vis Sci 2011; 52: 6279-6285 [PMID: 21474767 DOI: 10.1167/iovs.10-7081]
- O'Brien PD, Collum LM. Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep 2004; 4: 314-319 [PMID: 15175147 11 DOI: 10.1007/s11882-004-0077-2]
- 12 Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev 2016; 2: CD009729 [PMID: 26905373 DOI: 10.1002/14651858.CD009729.pub2]
- Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 2015; 112: 71-81; quiz 82 [PMID: 13 25686388 DOI: 10.3238/arztebl.2015.0071]
- Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M, Tsubota K. The effect of autologous serum eyedrops in the treatment of severe 14 dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 2005; 139: 242-246 [PMID: 15733983 DOI:



#### 10.1016/j.ajo.2004.08.040]

- 15 Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Kasper K, Geerling G. Corneal epitheliotrophic capacity of three different bloodderived preparations. Invest Ophthalmol Vis Sci 2006; 47: 2438-2444 [PMID: 16723454 DOI: 10.1167/iovs.05-0876]
- Celebi AR, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind 16 crossover study. Graefes Arch Clin Exp Ophthalmol 2014; 252: 619-626 [PMID: 24566903 DOI: 10.1007/s00417-014-2599-1]
- Azari AA, Rapuano CJ. Autologous serum eye drops for the treatment of ocular surface disease. Eye Contact Lens 2015; 41: 133-140 [PMID: 17 25603439 DOI: 10.1097/ICL.000000000000104]
- Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, Sullivan BD, Tomlinson 18 A, Tong L, Villani E, Yoon KC, Jones L, Craig JP. TFOS DEWS II Diagnostic Methodology report. Ocul Surf 2017; 15: 539-574 [PMID: 28736342 DOI: 10.1016/j.jtos.2017.05.001]
- 19 Schirmer O. Studien zur Physiologie und Pathologie der Tränenabsonderung und Tränenabfuhr. Graefes Arhiv für Ophthalmologie 1903; 56: 197-291 [DOI: 10.1007/BF01946264]
- 20 Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003; 22: 640-650 [PMID: 14508260 DOI: 10.1097/00003226-200310000-00008]
- 21 Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease. Arch Ophthalmol 1984; 102: 1049-1051 [PMID: 6378156 DOI: 10.1001/archopht.1984.01040030851031]
- 22 Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev 2017; 2: CD009327 [PMID: 28245347 DOI: 10.1002/14651858.CD009327.pub3]
- 23 López-Plandolit S, Morales MC, Freire V, Grau AE, Durán JA. Efficacy of plasma rich in growth factors for the treatment of dry eye. Cornea 2011; **30**: 1312-1317 [PMID: 22012030 DOI: 10.1097/ICO.0b013e31820d86d6]
- 24 Versura P, Profazio V, Campos EC. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr Eye Res 2010; 35: 553-564 [PMID: 20597641 DOI: 10.3109/02713683.2010.484557]
- Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ, Taylor HR. Controlled study of the use of autologous serum in dry eye 25 patients. Cornea 2001; 20: 802-806 [PMID: 11685055 DOI: 10.1097/00003226-200111000-00005]
- 26 Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface diseases. Arg Bras Oftalmol 2008; 71: 47-54 [PMID: 19274411]
- Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 2004; 88: 1467-1474 27 [PMID: 15489495 DOI: 10.1136/bjo.2004.044347]
- Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, Shimmura S. Treatment of dry eye by autologous serum application in Sjögren's 28 syndrome. Br J Ophthalmol 1999; 83: 390-395 [PMID: 10434857 DOI: 10.1136/bjo.83.4.390]
- Seghatchian J, Krailadsiri P. The platelet storage lesion. Transfus Med Rev 1997; 11: 130-144 [PMID: 9140172 DOI: 29 10.1053/tm.1997.0110130]
- Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with 30 keratoconjunctivitis sicca. Arthritis Rheum 1984; 27: 459-461 [PMID: 6712760 DOI: 10.1002/art.1780270415]





### Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

